GIM
HALO icon

Glenmede Investment Management’s Halozyme HALO Stock Holding History

Glenmede Investment Management’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$12.9M Buy
175,687
+6,396
+4% +$425K 0.06% 286
2025
Q2 		$8.81M Buy
+169,291
New +$9.63M 0.04% 370

Other funds holding HALO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Glenmede Investment Management's HALO Position: Q3 2025 in Review

Glenmede Investment Management increased its Halozyme (HALO) stake by 3.8% in Q3 2025, buying an estimated $425K and bringing the position to 175,687 shares worth $12.9M. The position accounts for 0.06% of the portfolio, ranked #286.

Glenmede Investment Management first reported a position in HALO in Q2 2025 and has held it in 2 quarters since. 602 funds tracked by Wall St. Rank hold HALO as of Q3 2025.

  • Glenmede Investment Management held 175,687 shares of Halozyme worth $12.9M as of Q3 2025.
  • Glenmede Investment Management bought 6,396 Halozyme shares in Q3 2025, an estimated $425K.
  • Halozyme made up 0.06% of Glenmede Investment Management's portfolio in Q3 2025, its #286 holding.
  • Glenmede Investment Management first reported a position in Halozyme in Q2 2025 and has held it in 2 quarters since.
  • 602 funds tracked by Wall St. Rank held Halozyme as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.